A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia

Published:2021-08-03 Issue:22 Volume:127 Page:4190-4197
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Klisovic Rebecca B.¹,Leung Wing H.²,Brugger Wolfram³,Dirnberger‐Hertweck Maren³,Winderlich Mark³,Ambarkhane Sumeet V.³,Jabbour Elias J.⁴^ORCID

Affiliation:

1. Department of Hematology and Medical Oncology Emory School of Medicine Atlanta Georgia

2. Department of Paediatrics and Adolescent Medicine The University of Hong Kong Pokfulam Hong Kong

3. MorphoSys AG Planegg Germany

4. The University of Texas MD Anderson Cancer Center Houston Texas

Funder

MorphoSys

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33796

Reference24 articles.

1. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

2. BESPONSA prescribing information.US Food & Drug Administration.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf. Accessed February 26 2021.

3. KYMRIAH prescribing information.US Food & Drug Administration.https://www.fda.gov/files/vaccines%2Cblood%26biologics/published/Package‐Insert‐‐‐KYMRIAH.pdf. Accessed February 26 2021.

4. BLINCYTO prescribing information.US Food & Drug Administration.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125557s017lbl.pdf. Accessed February 26 2021.

5. Recent Advances in Managing Acute Lymphoblastic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma;European Journal of Haematology;2024-07-12

2. Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts;Cancers;2024-03-26

3. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade;HemaSphere;2024-02

4. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

5. Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze;HemaSphere;2024-01